Michael Pisetsky Sells 19,600 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 19,600 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $20.15, for a total value of $394,940.00. Following the sale, the senior vice president owned 231,896 shares in the company, valued at approximately $4,672,704.40. The trade was a 7.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

SiBone Stock Up 0.6%

Shares of NASDAQ SIBN opened at $20.38 on Friday. The company has a quick ratio of 6.62, a current ratio of 7.97 and a debt-to-equity ratio of 0.21. The company has a market cap of $884.29 million, a P/E ratio of -39.96 and a beta of 0.76. SiBone has a 52 week low of $12.49 and a 52 week high of $20.80. The business has a 50-day simple moving average of $17.42 and a two-hundred day simple moving average of $16.86.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.05. SiBone had a negative return on equity of 12.86% and a negative net margin of 11.24%.The firm had revenue of $48.66 million for the quarter, compared to analysts’ expectations of $46.67 million. Research analysts anticipate that SiBone will post -0.78 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of SiBone in a research report on Monday, December 15th. Needham & Company LLC boosted their target price on SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Canaccord Genuity Group upped their target price on SiBone from $26.00 to $27.00 and gave the stock a “buy” rating in a research note on Wednesday. Morgan Stanley lifted their price target on SiBone from $20.00 to $23.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. Finally, Truist Financial boosted their price objective on SiBone from $21.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, SiBone currently has a consensus rating of “Moderate Buy” and an average target price of $25.00.

SiBone News Summary

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Canaccord raised its price target on SIBN from $26 to $27 and maintained a Buy rating, signaling stronger upside expectations that support further upside for the shares. Read More.
• Positive Sentiment: Truist increased its price target from $21 to $23 and kept a Buy rating, adding incremental broker support for the stock’s near-term rally. Read More.
• Positive Sentiment: Needham published a bullish forecast calling for strong price appreciation for SIBN, adding another institutional voice to the buy-side narrative. Read More.
• Positive Sentiment: Market headlines reported SIBN trading up roughly 5.4% after analyst upgrades, reflecting immediate market reaction to the research updates and lifting momentum. Read More.
• Negative Sentiment: CFO Anshul Maheshwari sold 18,542 shares at an average price of $20.15 (total ~$373,621); the filing shows his holding decreased about 9.1%. Insider selling can raise short-term concern about insider conviction, even if sales are for personal reasons. Read More.
• Negative Sentiment: SVP Michael A. Pisetsky sold 19,600 shares at an average of $20.15 (total ~$394,940); his position fell ~7.8% after the trade. Multiple insider disposals the same day can amplify investor caution. Read More.

Institutional Trading of SiBone

Several hedge funds and other institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of SiBone by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock valued at $343,000 after purchasing an additional 1,053 shares in the last quarter. Tudor Investment Corp ET AL lifted its stake in SiBone by 0.8% in the third quarter. Tudor Investment Corp ET AL now owns 258,032 shares of the company’s stock worth $3,798,000 after purchasing an additional 1,968 shares during the last quarter. Rhumbline Advisers boosted its position in SiBone by 3.6% during the first quarter. Rhumbline Advisers now owns 59,721 shares of the company’s stock valued at $838,000 after buying an additional 2,100 shares during the period. Franklin Resources Inc. grew its stake in shares of SiBone by 8.3% during the third quarter. Franklin Resources Inc. now owns 29,018 shares of the company’s stock valued at $427,000 after buying an additional 2,228 shares during the last quarter. Finally, EntryPoint Capital LLC increased its holdings in shares of SiBone by 21.5% in the first quarter. EntryPoint Capital LLC now owns 14,787 shares of the company’s stock worth $207,000 after buying an additional 2,613 shares during the period. Hedge funds and other institutional investors own 98.11% of the company’s stock.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.